Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis

Pavan K. Vaddady, Ashit Trivedi, Chetan Rathi, Dora B. Madhura, Jiuyu Liu, Richard E. Lee, Bernd Meibohm

Research output: Contribution to journalArticle

Abstract

Spectinamides are a novel class of antibiotics under development for the treatment of MDR- and XDR-tuberculosis, with 1599 and 1445 as early lead candidates within this group. In order to evaluate and differentiate the pharmacological properties of these compounds and assist in candidate selection and design of optimal dosing regimens in animal models of Mtb infection, time kill curve assessments were performed in a previously established in vitro PK/PD model system. The performed studies and subsequent pharmacometric analysis indicate that the anti-mycobacterial activity of 1599 exhibits concentration-dependent killing whereas 1445 shows time-dependent killing. These findings are supported by the fact that the PKPD index that best describes bacterial killing is T > MIC for 1445, but fCmax/AUC for 1599. The differential killing behavior among the lead candidates can be rationalized by the differences in post-antibiotic effect: 15.7 h for 1445 compared the 133 h for 1599. Overall, the PK/PD based analysis of the in vitro pharmacologic killing profile of spectinamides 1599 and 1445 on mycobacteria provided valuable insights that contributed to lead candidate selection and preclinical development of these compounds.

LanguageEnglish (US)
Pages233-239
Number of pages7
JournalEuropean Journal of Pharmaceutical Sciences
Volume127
DOIs
StatePublished - Jan 15 2019

Fingerprint

Tuberculosis
Anti-Bacterial Agents
Multidrug-Resistant Tuberculosis
Mycobacterium
Area Under Curve
Animal Models
Pharmacology
Infection
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis. / Vaddady, Pavan K.; Trivedi, Ashit; Rathi, Chetan; Madhura, Dora B.; Liu, Jiuyu; Lee, Richard E.; Meibohm, Bernd.

In: European Journal of Pharmaceutical Sciences, Vol. 127, 15.01.2019, p. 233-239.

Research output: Contribution to journalArticle

Vaddady, Pavan K. ; Trivedi, Ashit ; Rathi, Chetan ; Madhura, Dora B. ; Liu, Jiuyu ; Lee, Richard E. ; Meibohm, Bernd. / Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis. In: European Journal of Pharmaceutical Sciences. 2019 ; Vol. 127. pp. 233-239.
@article{efe9097793d34940a36876bd1746d1eb,
title = "Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis",
abstract = "Spectinamides are a novel class of antibiotics under development for the treatment of MDR- and XDR-tuberculosis, with 1599 and 1445 as early lead candidates within this group. In order to evaluate and differentiate the pharmacological properties of these compounds and assist in candidate selection and design of optimal dosing regimens in animal models of Mtb infection, time kill curve assessments were performed in a previously established in vitro PK/PD model system. The performed studies and subsequent pharmacometric analysis indicate that the anti-mycobacterial activity of 1599 exhibits concentration-dependent killing whereas 1445 shows time-dependent killing. These findings are supported by the fact that the PKPD index that best describes bacterial killing is T > MIC for 1445, but fCmax/AUC for 1599. The differential killing behavior among the lead candidates can be rationalized by the differences in post-antibiotic effect: 15.7 h for 1445 compared the 133 h for 1599. Overall, the PK/PD based analysis of the in vitro pharmacologic killing profile of spectinamides 1599 and 1445 on mycobacteria provided valuable insights that contributed to lead candidate selection and preclinical development of these compounds.",
author = "Vaddady, {Pavan K.} and Ashit Trivedi and Chetan Rathi and Madhura, {Dora B.} and Jiuyu Liu and Lee, {Richard E.} and Bernd Meibohm",
year = "2019",
month = "1",
day = "15",
doi = "10.1016/j.ejps.2018.11.006",
language = "English (US)",
volume = "127",
pages = "233--239",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis

AU - Vaddady, Pavan K.

AU - Trivedi, Ashit

AU - Rathi, Chetan

AU - Madhura, Dora B.

AU - Liu, Jiuyu

AU - Lee, Richard E.

AU - Meibohm, Bernd

PY - 2019/1/15

Y1 - 2019/1/15

N2 - Spectinamides are a novel class of antibiotics under development for the treatment of MDR- and XDR-tuberculosis, with 1599 and 1445 as early lead candidates within this group. In order to evaluate and differentiate the pharmacological properties of these compounds and assist in candidate selection and design of optimal dosing regimens in animal models of Mtb infection, time kill curve assessments were performed in a previously established in vitro PK/PD model system. The performed studies and subsequent pharmacometric analysis indicate that the anti-mycobacterial activity of 1599 exhibits concentration-dependent killing whereas 1445 shows time-dependent killing. These findings are supported by the fact that the PKPD index that best describes bacterial killing is T > MIC for 1445, but fCmax/AUC for 1599. The differential killing behavior among the lead candidates can be rationalized by the differences in post-antibiotic effect: 15.7 h for 1445 compared the 133 h for 1599. Overall, the PK/PD based analysis of the in vitro pharmacologic killing profile of spectinamides 1599 and 1445 on mycobacteria provided valuable insights that contributed to lead candidate selection and preclinical development of these compounds.

AB - Spectinamides are a novel class of antibiotics under development for the treatment of MDR- and XDR-tuberculosis, with 1599 and 1445 as early lead candidates within this group. In order to evaluate and differentiate the pharmacological properties of these compounds and assist in candidate selection and design of optimal dosing regimens in animal models of Mtb infection, time kill curve assessments were performed in a previously established in vitro PK/PD model system. The performed studies and subsequent pharmacometric analysis indicate that the anti-mycobacterial activity of 1599 exhibits concentration-dependent killing whereas 1445 shows time-dependent killing. These findings are supported by the fact that the PKPD index that best describes bacterial killing is T > MIC for 1445, but fCmax/AUC for 1599. The differential killing behavior among the lead candidates can be rationalized by the differences in post-antibiotic effect: 15.7 h for 1445 compared the 133 h for 1599. Overall, the PK/PD based analysis of the in vitro pharmacologic killing profile of spectinamides 1599 and 1445 on mycobacteria provided valuable insights that contributed to lead candidate selection and preclinical development of these compounds.

UR - http://www.scopus.com/inward/record.url?scp=85056457067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056457067&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2018.11.006

DO - 10.1016/j.ejps.2018.11.006

M3 - Article

VL - 127

SP - 233

EP - 239

JO - European Journal of Pharmaceutical Sciences

T2 - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -